RedHill Biopharma Ltd., the specialty biopharmaceutical company with a U.S. commercial office in Raleigh, North Carolina, announced on September 1, 2026 that it acquired exclusive global and U.S. commercialization rights to Ferring Pharmaceuticals’ Rebyota® and Clenpiq® for a $12 million upfront payment, plus tiered royalties on net sales and potential milestone payments. CEO Dror Ben-Asher framed it as the second half of a deliberate strategy: “We have executed a clear strategic sequence. We have monetized Talicia for $18 million cash upfront, plus $35 million in potential upside, used $12 million to secure commercialization rights to two established, proprietary, FDA-approved gastrointestinal drugs, that collectively generated approximately $37.5 million in U.S. net sales in 2025, and emerged with a materially larger, fully controlled commercial business and a stronger liquidity position.”
Two Drugs Already Generating Revenue
Rebyota is a first-in-class microbiota-based therapy for preventing recurrent C. difficile infection in adults following antibiotic treatment, FDA-approved in 2022 and holding Breakthrough Therapy and Orphan Drug designations, with patent protection potentially extending to 2036. Clenpiq is a ready-to-drink, low-volume bowel preparation for colonoscopy approved for patients 9 and older. Chief Commercial Officer Rick Scruggs laid out what each is already doing in the market: “Rebyota generated approximately $16.9 million in U.S. net sales in 2025 through its clinical profile, broad coverage and an established customer base of approximately 600 active accounts. Clenpiq, a ready-to-drink low-volume bowel preparation on the U.S. market, delivered $20.6 million in net sales in 2025, with minimal promotion. Together the two assets give RedHill a significantly stronger commercial growth engine in both the U.S. and other new territories.” Rebyota currently has coverage across 93% of U.S. lives, and Clenpiq has unrestricted coverage across 63%.
Addressing a Costly, Recurring Infection
C. difficile infection causes an estimated 3.6 million cases globally each year, including roughly 500,000 in the U.S., where it kills about 30,000 people annually and drives roughly 165,000 recurrences; Rebyota has shown a greater than 70% success rate in preventing recurrence in that population. RedHill funded the acquisition with proceeds from its earlier, separately announced $18 million divestiture of Talicia, which carries up to $35 million in additional potential upside. Ben-Asher tied the combined moves to what comes next for the company: “This, combined with RedHill’s experienced and lean commercial team and proven development capabilities, creates a scalable foundation for further growth, including additional acquisition of complementary revenue-generating products.”
About RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies Rebyota®, for the prevention of recurrent C. diff infection, and the bowel preparation treatment Clenpiq®, alongside a late-stage pipeline that includes opaganib, RHB-102, RHB-204, and RHB-107.
